Whitepapers

Light scattering facilitates vaccine development by enabling the analysis of size, shape, molar mass, and other parameters derived from these properties.

Many biologics must undergo freeze-thaw stability testing during product development. We describe a method for performing this test using a DLS plate reader.

SEC-MALS quantifies biophysical attributes of mRNA, including molar mass, percent aggregates, Rg and Rh, and how they are affected by formulation and storage conditions.

Industry changes can often introduce additional risks to the sterile fill/finish process, resulting in production delays, additional costs, and safety concerns. Choose Eurofins BioPharma Product Testing to help eliminate associated risks.

Join Eurofins BioPharma Product Testing and Vanrx (now part of Cytiva), for an in-depth discussion covering ways to eliminate human error and other associated risks when producing small batches of sterile GMP product for Phase 1 and 2 clinical trials. Learn how we can help increase speed and flexibility to drive your drug product into the clinic, and ultimately to patients faster.

Eurofins BioPharma Product Testing in San Diego can help you realize the golden potential of your investigational new drug, including formulation and fill/finish services.

Eurofins BioPharma Product Testing can help eliminate human error and other associated risks when producing small batches of sterile GMP product for Phase I-II trials using our state-of-the-art Vanrx Microcell Vial Filler.

Innovations in the use of viral vectors as a gene delivery vehicle are a key factor in the growth of the gene and cell therapy field. However, the long-term impact of viral vectors requires continued research in their design to address both efficacy and the problems with immunogenicity and toxicity.

This benchmarking study compares the Advanced Instruments Solentim ICON™ viability assay to the performance of a commercially available cell counter. The results demonstrate lower variation, increased precision, and time savings.

There’s no doubt clinical research has changed. With 77% of surveyed pharma executives planning to run a hybrid or decentralized trial this year, it’s important to understand the benefits of web-enabled research tools and how they work. Learn the benefits of DCTs with this eBook.

Medable eConsent improves the trial experience for patients, sites, & sponsors. Learn how eConsent in conjunction with other decentralized solutions helped save one organization save $20M in trial costs, reduce trial site visits by 75%, and cut enrollment timelines in half with this case study.

The goal of this paper is to introduce and support the use of osmolality in the Downstream Ultrafiltration/Diafiltration (UF/DF) process steps in the mAb workflow.

The data is conclusive, DCTs provide better returns on investment than traditional trials. In fact, new analysis by Tufts CSDD shows DCTs can provide up to 13x ROI in phase III trials & 5x ROI in phase II trials through reductions in clinical trial cycle time, screen failure decreases, and more. Learn more with your free copy of the analysis.

A recent study by Morning Consult finds that >54% of US adults would be willing to participate in a clinical trial if it had a 30-minute-or-less commute. This is quite striking, given that <4% of the 328 million people in America are actively participating in clinical research today. The solution? - An accessible, intuitive digital clinical platform that connects sponsors, sites & patients, and replaces burdensome paper forms and physical visits with electronic consents (eConsent), electronic Clinical Outcome Assessments (eCOA’s), and remote visits (TeleVisits). Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now to learn how.

This benchmarking study compares the Advanced Instruments Solentim ICON™ viability assay to the performance of a commercially available cell counter. The results demonstrate lower variation, increased precision, and time savings.

The goal of this paper is to introduce and support the use of osmolality in the Downstream Ultrafiltration/Diafiltration (UF/DF) process steps in the mAb workflow.

Using a pre-packed column platform enables seamless scale-up for downstream process purification. We demonstrate that neither the capacity of the packed resin nor the separation efficiency is affected when increasing the column volume.

The 5’ capping is a CQA for mRNA vaccines and therapeutics, and needs to be fully characterized. Learn a sensitive, robust LC-HRAM-MS/MS method for identification and quantitation of 5’ cap.

Learn about the key benefits of adding automation to flow imaging microscopy and how these are implemented in ALH for FlowCam™

In this application note we show how flow imaging microscopy and FlowCam can help analyze particles in biotherapeutic samples. To demonstrate this ability, a simulated protein formulation consisting of silicone oil microdroplets spiked in a protein formulation was prepared and run on a FlowCam 8100 FIM instrument and analyzed with VisualSpreadsheet software.